英文药名：ultibro（Glycopyrronium Bromide inhalation capsules）

中文药名：格隆溴铵吸入胶囊

生产厂家：瑞士诺华日本公司
药品介绍
适用症
缓解慢性支气管炎，肺气肿
剂量和用法
通常情况下，它被吸入与设备的辅助吸入此药每日一次只（110μg如茚达特罗和50μg的为格隆）一旦胶囊成人。
注意事项
这种药物可以用于治疗慢性阻塞性肺疾病的症状的长期管理。这种药物是不被用于急性治疗的目的在慢性阻塞性肺疾病的发作的药物。
包装规格
格隆溴铵吸入胶囊*14粒
格隆溴铵吸入胶囊*28粒

完整资料附件：http://www.info.pmda.go.jp/go/pack/2259805G1027_1_03/
Once-daily Ultibro® Inhalation Capsules (QVA149) for COPD Launched in Japan
Dual bronchodilation with Ultibro® is expected to set a new standard of care in COPD by combining the proven efficacy benefits and safety profiles of two established Novartis COPD treatments, the LABA*, Onbrez® Inhalation Capsules (indacaterol), and the LAMA**, Seebri® Inhalation Capsules (glycopyrronium bromide). All Novartis inhaled COPD portfolio products are developed for delivery via a single-dose dry powder inhaler (SDDPI) called the Breezhaler® inhalation device which has low air flow resistance, making it suitable for patients with airflow limitation1. The Breezhaler® device allows patients to hear, feel and see that they have taken the full dose correctly.
Ultibro® was approved in Japan and EU (under the brand name Ultibro® Breezhaler®) in September, and has since been launched in Germany and Netherlands. US submission is anticipated in the second half of 2014.
Ultibro®, Seebri®, Onbrez® and Breezhaler® are registered trademarks of Novartis AG.
* a long-acting beta2-adrenergic agonist,
** a long-acting muscarinic antagonist
About Seebri®
Once-daily Seebri® Breezhaler® (EU)/ Seebri® Inhalation Capsules (Japan), (“Seebri”; glycopyrronium bromide), is a novel inhaled long-acting muscarinic antagonist (LAMA) indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. Seebri® was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura. Seebri® was first approved in the EU and Japan in September 2012 as a maintenance bronchodilator treatment for COPD, and has been approved in over 50 countries including Canada and Australia. Seebri® has been launched in Germany, the UK, Japan and other major markets.
The US filing is expected in the first half of 2014.
About COPD
COPD is a chronic, progressive lung disease that is commonly caused by tobacco smoking, air pollution or occupational exposure, and results in airflow obstruction and debilitating bouts of breathlessness. Although the latest figures show only 220,000 people have been diagnosed with COPD in Japan,